M
MIRA PHARMACEUTICALS, INC.
MIRACIK 0001904286NasdaqEmerging GrowthPharmaceutical PreparationsFlorida
Period
FY 2025
Revenue
—
Net Income
$-10.40M
Total Assets
$11.09M
Equity
$10.40M
Shares Out
42.02M
Op. Cash Flow
$-4.70M
Business
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical development company advancing neuroscience programs for neurologic and neuropsychiatric disorders. It is developing Ketamir-2, a patent-pending oral ketamine analog in clinical development for neuropathic pain and depression-related indications, and MIRA-55, an oral cannabinoid analog in preclinical development for cognitive function, neuroinflammation and pain. Its operations focus on research and development, IND-enabling studies, clinical trials and CDMO manufacturing partnerships. The company holds exclusive rights in the U.S., Canada and Mexico and advances programs through CROs, clinical sites and distribution via development and commercialization partners.
Summary from filing dated 2025-03-28
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Revenues | — | — | — | — | |
| General and administrative expenses | 9 | 5 | 6 | 3 | |
| Research and development expenses | 2 | 3 | 2 | 2 | |
| Total operating costs | 10 | 8 | 9 | 7 | |
| Interest income | 98,911 | 165,669 | — | — | |
| Other expense | −13,072 | — | — | — | |
| Unrealized loss on short-term investment | −35,212 | — | — | — | |
| Total other income, net | 50,627 | 165,669 | — | — | |
| Net Loss | −10 | −8 | −12 | −7 | |
| Deemed dividend | −22 | — | — | — | |
| Net loss attributable to common stockholders | −32 | −8 | — | — | |
| Basic loss per share | −1.35 | −0.51 | −0.85 | −0.4 | |
| Diluted loss per share | −1.35 | −0.51 | −0.85 | −0.4 | |
| Basic weighted average common stock shares outstanding | 24 | 15 | 14 | 18 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-04-30 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash | 6 | 3 | — | — | — | |
| Prepaid expenses | 28,146 | 54,729 | — | 243,802 | — | |
| Short-term investment, at fair value related party | 5 | — | — | — | — | |
| Total current assets | 11 | 3 | — | 5 | 494,405 | |
| Total assets | 11 | 3 | — | 5 | 858,074 | |
| Trade accounts payable and accrued liabilities | 129,203 | 723,349 | — | — | — | |
| Due to related party | 572,865 | — | — | — | — | |
| Total current liabilities | 702,068 | 723,349 | — | 558,097 | 1 | |
| Total liabilities | 702,068 | 723,349 | — | 558,097 | 1 | |
| Commitments and contingencies (Note 7) | — | — | — | — | — | |
| Preferred Stock, $0.0001 par value, 10,000,000 shares authorized and none issued or outstanding. | — | — | — | — | — | |
| Common Stock, $0.0001 par value; 100,000,000 shares authorized, 41,938,587 and 16,560,852 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively. | 4,194 | 1,656 | — | 1,478 | 6,657 | |
| Additional paid-in capital | 50 | 31 | 148,703 | 26 | 9 | |
| Accumulated deficit | −40 | −29 | — | −21 | −9 | |
| Total stockholders equity | 10 | 2 | — | 4 | −596,232 | |
| Total liabilities and stockholders equity | 11 | 3 | — | 5 | 858,074 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Stock-based compensation expense | 6 | 2 | 3 | 1 | |
| Prepaid expenses | 26,583 | 189,073 | −243,802 | — | |
| Other receivables | — | 11,862 | −11,862 | — | |
| Trade accounts payable and accrued expenses | −594,146 | 184,785 | −389,524 | 152,081 | |
| Related party accrued interest | — | −14,472 | — | — | |
| Net cash used in operating activities | −5 | −6 | −5 | −6 | |
| Offering costs | −292,470 | — | 143,427 | −43,427 | |
| Proceeds from related party | 572,865 | — | — | — | |
| Proceeds from Common stock option exercises | 888,282 | — | — | — | |
| Advances from (to) affiliates | — | 33,713 | — | — | |
| Bayshore Trust short-swing disgorgement | — | 148,703 | — | — | |
| Proceeds from sale of common stock | 7 | 4 | 8 | 3 | |
| Net cash provided by financing activities | 8 | 4 | 9 | 3 | |
| Net increase (decrease) in cash | 4 | −2 | 4 | −2 | |
| Cash paid for interest | — | — | — | — | |
| Cash paid for income taxes | — | — | — | — | |
| Deferred offering costs charged to additional paid-in capital | — | 32,500 | 426,345 | — | |
| Issuance of common stock for the short-term investments, SKNY acquisition | 5 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro